GSK GlaxoSmithKline
- 40.650
- -0.460-1.12%
- 40.665
- +0.015+0.04%
GlaxoSmithKline News
CDC 'Preparing for the Possibility' Bird Flu Could Spread More Easily
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says
Moderna's (MRNA) newly approved respiratory syncytial virus vaccine may achieve stronger than expected US penetration despite entering a market with two seasoned competitors, Oppenheimer said in a Wed
Express News | World Health Organization Chief: At This Time, Who Continues To Assess Risk To Public Health From H5n1 As Low
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation
GSK (GSK) said Monday it started the appeal process of a recent ruling by the Delaware Superior Court to allow plaintiff expert testimony in the litigation related to the heartburn drug Zantac.
GSK's Zantac Litigation Concerns Are Overblown -- Market Talk
0925 GMT - GSK's Zantac litigation has disproportionately weighed on the share since the demerger of Haleon and overshadowed its improving growth outlook, Shore Capital Markets analyst Sean Conroy say
Zantac's cancer lawsuit continues to be reviewed, and GlaxoSmithKline (GSK.US) has filed an appeal.
According to Zhicheng Finance APP, GlaxoSmithKline (GSK.US) and other pharmaceutical companies have appealed the ruling allowing Zantac carcinogenic lawsuits to continue in Delaware. It is reported that this ruling allows more than 70,000 lawsuits claiming that the anti-heartburn drug Zantac can cause cancer to continue to be tried. This ruling has caused a sharp drop in GlaxoSmithKline's stock price. If Judge Vivian Medinilla of the Delaware Superior Court approves the appeal request filed by companies including Pfizer (PFE.US), Sanofi (SNY.US) and Boehringer Ingelheim, the appeal will be submitted directly.
GSK Sees Dismissal of US Zantac Case Without Settlement
GSK (GSK.L) said Monday that a case related to its heartburn drug Zantac in the US state of Illinois was voluntarily dismissed by the plaintiff. The case was expected to go to trial the same day. The
Express News | GSK States Scientific Consensus Finds No Consistent Evidence Linking Zantac (Ranitidine) To Cancer; No Settlement Or Payment Made In Ms. Kasza's Voluntary Dismissal
Moderna Combination Shot Outperforms Standalone Flu, Covid-19 Jabs
An experimental Moderna vaccine that protects against flu and Covid-19 performed better than stand-alone flu and Covid-19 shots in a large trial, the company said Monday.
GSK Secures Expanded US FDA Approval for RSV Vaccine
GSK (GSK.L) received an expanded age indication from the US Food and Drug Administration for the Arexvy vaccine for the respiratory syncytial virus, or RSV. The vaccine was approved for adults aged be
Statement: Zantac (Ranitidine) Litigation – GSK Starts Process for Appeal of Recent Delaware Daubert Decision
Delaware Superior Court's ruling inconsistent with how Daubert standard* has previously been applied in Delaware and federal courts Application has been filed seeking right of appeal to the Delaware
Statement: Zantac (Ranitidine) Litigation – Kasza Case
GSK plc (LSE/NYSE: GSK) welcomes the plaintiff's voluntary dismissal of the next Zantac case (Kasza), which was scheduled to start trial in Illinois state court on 10 June 2024. GSK did not settle Ms
GSK, SpringWorks End Collaboration Agreement
GSK Wins FDA Nod to Expand Label for RSV Vaccine
GSK (NYSE:GSK) announced late Friday that the U.S. FDA approved Arexvy, its vaccine against the respiratory syncytial virus (RSV) for adults aged 50–59 years at increased risk of infection, expanding its current label for older adults.
GSK Vaccine to Prevent Respiratory-Tract Disease Approved for Expanded Use
GSK said on Friday that its vaccine to prevent respiratory-tract disease has been approved for expanded usage in the U.S. by the Food and Drug Administration.
FDA Approves GSK's RSV Vaccine for High-risk Adults Ages 50 to 59, Expanding Shot's Reach
The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more vulnerable to severe cases of the virus. The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
Express News | SpringWorks Therapeutics Inc Says Termination Of License Deal Does Not Trigger Any Payment Obligations On Part Of Co/any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Says Termination Does Not Affect Co's Rights To Continue Developing Or Commercializing Its Products Or Product Candidates; Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics:Deal Termination Between Co & Glaxosmithkline Intellectual Property Development Effective 180 Days After Notice Receipt
SpringWorks Therapeutics Got Notice Of Termination Of Amended & Restated Collaboration And License Agreement, Dated Sept 6, 2022, Between Co & GSK
SpringWorks Therapeutics Got Notice Of Termination Of Amended & Restated Collaboration And License Agreement, Dated Sept 6, 2022, Between Co & GSK
Analysis
Price Target
No Data
